![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0107.png)
Baguley et al.
post-MMT, the presence of residual radiological and/or en-
doscopic disease despite symptomatic control may increase
risk of symptom relapse.
4
The presence or degree of disease
burden post-MMT may play a critical role in determining
chronicity and whether further treatment is required, in-
dependent of symptom status. The influence of post-MMT
symptoms and their correlation to radiological appearance
post-MMT are assessed.
Patients and methods
A retrospective cohort of patients treated at a tertiary rhi-
nology clinic was assessed. All data were collected prospec-
tively. The study had prior institutional ethics review ap-
proval from St Vincent’s Hospital.
Population
Inclusion criteria were radiologic confirmation of diffuse
mucosal disease and a history consistent with major or mi-
nor CRS symptoms
5
or fulfilling the current European Po-
sition Paper
<
on Rhinosinusitis and Nasal Polyps (EPOS)
classification.
3
Atopic status (by history or blood/skin prick
test), history of asthma, smoking, previous surgery, and
aspirin-sensitive airways disease (ASAD) were recorded. Pa-
tients with suspected comorbidities such as migraine, atypi-
cal facial pain, and allergic rhinitis were included as long as
they met the inclusion criteria of both radiologically con-
firmed mucosal changes and CRS symptoms. Patients with
clear indications for surgery, such as mucoceles, extensive
fungal disease, and uncinate atelectasis, and those with iso-
lated sinus disease (eg, sphenoid or odontogenic sinusitis)
were excluded. Patients who had recently had prednisone
courses and remained symptomatic and requested surgery
rather than further medical treatment were also excluded.
MMT
MMT consisted of oral prednisone for 3 weeks (1 week
each of 25 mg/day, 12.5 mg/day, and 5 mg/day), topi-
cal steroids in spray or irrigation form, and saline irriga-
tion. Antibiotics were given whenever discolored discharge
from the middle meatus was observed and in these cases
swabs were taken from the middle meatus with endoscopic
guidance. Amoxicillin/clavulanic acid was prescribed for
20 days and the antibiotic was altered if indicated by sub-
sequent culture. Atopic patients were not offered oral an-
tihistamines or antileukotrienes. For the included group
follow-up was arranged in 4 to 6 weeks (later if requested
by the patient) to assess response to medical therapy.
Clinical outcomes
Patient-reported outcomes consisted of nasal symptom
scores (NSS), and disease specific quality of life (QOL)
scores (22-item SinoNasal Outcomes Test [SNOT-22]).
6
Nasal symptoms were nasal obstruction, rhinorrhea, post-
nasal discharge, loss of smell, and facial pain/pressure, each
scored on a scale of 0 to 5. SNOT-22 scores were tallied
both initially and post-MMT and reported as means.
Clinically reported status of CRS post-MMT was de-
fined as “controlled” if symptoms had resolved or were not
bothersome.
3
This was recorded post-MMT only because
all patients were symptomatic for CRS initially.
Endoscopic outcomes
Endoscopic images were captured digitally at both pre-
MMT and post-MMT visits with archived images from
the latter visits assessed using the Lund-Kennedy scor-
ing system as well as EPOS 2012 definitions of “positive
endoscopy.”
3,7
Radiological outcomes
CT scans were performed with a Xoran miniCAT
TM
low-
dose cone-beam scanner (Xoran Technologies Inc., Ann
Arbor, MI), which delivers an equivalent radiation dose
of 0.17 mSv per sinus CT series. CT scans were scored as
described by Lund and Mackay
8
and were given a clinician-
assigned category of “resolved” or “persistent inflamma-
tion.” Mucosal cysts and minor isolated thickening of the
maxillary sinus floor were considered neither to represent
CRS nor to influence the LM scores.
Patients were thus grouped according to the presence or
absence of both ongoing symptoms and objective evidence
of inflammation (see Fig. 1, results).
Patients were followed as required to assist with ongoing
therapy and asked to represent should symptoms recur after
discharge.
Statistical analysis
Data were analyzed using IBM SPSS Statistics v20 (IBM
Corp., Chicago, IL). Descriptive data are presented as per-
centages with mean
±
standard deviation (SD) for para-
metric data and median and interquartile range (IQR)
for nonparametric data. Chi-square tests were used for
categorical variables with the Fisher exact test for cell
counts
<
5. Parametric data were compared with 1-way
analysis of variance (ANOVA) and nonparametric data
with the Mann-Whitney U test or Kruskal-Wallis test for
3 or more independent samples. Statistical significance was
reported for alpha of 0.05.
Results
A total of 86 patients (38% female, age 46
±
13 years)
met inclusion criteria and had post-MMT CT scans avail-
able for review. Nasal polyposis was evident in 31%, al-
lergy/atopy in 37%, asthma in 28%, and ASAD in 2%;
13% were smokers and 10% had undergone previous
sinus surgery.
MMT consisted of a 3-week course of prednisone with
daily intranasal corticosteroids and saline irrigation for all
patients with antibiotic treatment given to 53% patients,
usually amoxicillin/clavulanic acid for 20 days. The median
International Forum of Allergy & Rhinology, Vol. 4, No. 7, July 2014
85